MILAN and BOSTON, Oct. 14, 2022 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, announced today that the Company will present findings examining how Chronic Lung Allograft Dysfunction (CLAD) is the leading cause of re-transplantation and associated with high healthcare costs during a rapid oral session at the American College of Chest Physicians® (CHEST) 2022 Annual Meeting being held October 16 – 19, 2022 in Nashville, TN.
BASEL, Switzerland, Nov. 11, 2021 / PRNewswire / - Luye Pharma Group (Luye Pharma) announced today that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Zambon Switzerland (Zambon) that Zambon will be the exclusive Rights to market Rivastigmine Multi-Day Transdermal Patches (Rivastigmine MD) granted in Switzerland.
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Bo Jesper Hansen has informed the Board of Directors of his intention to step down as a Non-Executive Director, effective from this year’s Annual Shareholders Assembly taking place on March 27, 2018.
Zambon`s Xadago (Safinamide Methanesulfonate) Approved in Europe For Parkinson’s Disease
Zambon’s Xadago (Safinamide) Approved In Europe For Mid-Late Stage PD Patients
Safinamide New Drug Application (NDA) Re-submitted to the US Food and Drug Administration (FDA)